David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.